Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.10.0.1
Revenue Recognition - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Disaggregation of Revenue [Line Items]          
Total revenues $ 263,685 $ 292,601 $ 518,598 $ 558,981  
Contract liability 109,600   109,600   $ 140,400
Rayaldee          
Disaggregation of Revenue [Line Items]          
Revenue recognized 4,800   8,500    
Total revenues     13,582    
Transfer of intellectual property and other          
Disaggregation of Revenue [Line Items]          
Total revenues 19,107 29,723 34,855 45,328  
Pfizer | Collaborative Arrangement, Product          
Disaggregation of Revenue [Line Items]          
Contract liability 100,100   100,100    
Pfizer | Collaborative Arrangement, Product | Transfer of intellectual property and other          
Disaggregation of Revenue [Line Items]          
Total revenues $ 16,300 $ 18,300 $ 31,000 $ 32,400